The therapeutic potential of HDAC inhibitors as anticancer agents resulted in the FDA approval of four HDAC inhibitors (SAHA, FK228, PDX101, and LBH589) to date against T-cell lymphoma and multiple myeloma [14]; however, there are currently no FDA approved HDAC inhibitors against NE cancers. The gene discussed is HDAC9; the disease is AL amyloidosis.